Help Us Protect Access to Sexual and Reproductive Health Care Today!
May 01
Lisa Maldonado, co-author of Community Health Centers’ Role in Family Planning discusses her ACU Column, published in the May 2013 issue of the Journal of Health Care for the Poor and Underserved.
May 01
How long do IUDs remain effective? After the FDA approved the progestin (Mirena) and copper (Paragard) IUDs, further studies supported two extra years of use for each device.
Mar 01
When a woman needs emergency contraception (EC), remember the Copper IUD! This Contraceptive Pearl covers use of the Copper IUD as emergency contraception.
Feb 01
Skyla contains 13.5mg of levonorgestrel and provides up to three years of protection against pregnancy. Learn all about this new intrauterine device in this Contraceptive Pearl.
Apr 10
Cost is one of the biggest barriers to accessing effective hormonal birth control. Read this Contraceptive Pearl to find out about low-cost options for hormonal birth control.
Feb 14
Since EC isn’t available over-the-counter to everyone yet, clinicians should be well-versed in the different types of emergency contraception. This Contraceptive Pearl details the different types so clinicians can know what will work best for their patients.
Dec 01
Contraception is especially important for HIV+ women due to the risks that pregnancy can bring on. Different types of contraception and how they work for HIV+ women are detailed in this Contraceptive Pearl.
Nov 01
Several researchers have tried to find a counseling approach that leads women to stick with their contraceptive method longer. So far, the results are disappointing! This Contraceptive Pearl discusses why adherence is low and what clinicians can do about it.
Oct 10
This Contraceptive Pearl covers the best practice to confidentially discuss and prescribe contraception with teens.
Sep 01
Studies of the contraceptive patch and Deep Vein Thrombosis (DVT) have yielded conflicting results. In 2006, two trials found a higher incidence of nonfatal blood clots among women using the patch than among women taking oral contraceptives, while a third study found no significant difference. How can we frame this discussion so that we communicate honestly without alarming patients?